Better understanding of the mechanisms of action, modification and synthesis of antimicrobial peptides is reigniting commercial development. Jeffrey L. Fox reports.
This is a preview of subscription content, log in via an institution to check access.
Change history
27 June 2013
In the version of this article initially published, the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company’s name is NAICONS.
01 December 2013
In the May 2013 news analysis “Antimicrobials stage a comeback” (Nat. Biotechnol. 31, 379–382, 2013), the Italian company researching the use of novel antibiotics was erroneously identified as NeED Pharmaceuticals. The company's name is NAICONS. The error has been corrected in the PDF and HTML versions of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, J. Antimicrobial peptides stage a comeback. Nat Biotechnol 31, 379–382 (2013). https://doi.org/10.1038/nbt.2572
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2572
- Springer Nature America, Inc.
This article is cited by
-
Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus
Journal of Biomedical Science (2024)
-
Interaction of designed cationic antimicrobial peptides with the outer membrane of gram-negative bacteria
Scientific Reports (2024)
-
In Silico Designing of Antimicrobial Peptide Cocktail Drug Against SARS-CoV-1 and SARS-CoV-2 Replisome Complex
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences (2024)
-
Candida albicans and Antifungal Peptides
Infectious Diseases and Therapy (2023)
-
Systematic identification and characterization of repeat sequences in African swine fever virus genomes
Veterinary Research (2022)